| Name | Title | Contact Details |
|---|
LJUNGSTRÖM is a historic company with over 100 years of expertise in advanced environmental solutions, focusing on heat recovery and emissions control. Founded in 1923 by Fredrik Ljungström, the company is known for inventing the worlds first air preheater, which significantly improved energy efficiency in power plants. Today, LJUNGSTRÖM is a global leader in industrial flue gas management technologies and custom-engineered assemblies. The company offers a range of products, including its flagship Ljungström air preheater, which enhances thermal efficiency in steam power plants by recovering waste heat from flue gases. Additionally, LJUNGSTRÖM provides gas-gas heaters that further improve plant efficiency and custom-engineered solutions for emissions control. Their services aim to optimize plant performance and reduce CO₂ emissions, contributing to sustainability in the energy and industrial sectors. LJUNGSTRÖM serves a diverse international customer base across more than 100 countries, focusing on power generation plants and industrial facilities. The company is committed to innovation, operational excellence, and environmental sustainability, aiming to lead the industry in energy efficiency and impact.
Alvarez Stauffer Bremer PLLC is a full service law firm, located in downtown Houston, specializing in Pre-Litigation Disputes, Commercial Litigation, Energy Litigation, Mass Tort and Catastrophic Incident Litigation, Arbitration, and eDiscovery. ASB proudly represents international energy companies, large health-care and hospital systems, and pipeline operators — not to mention individuals and closely held companies.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Located in Nashville, TN, Paladin capital is a premier leader in business acquisition, and ownership transfer, via Employee Stock Ownership Plans (ESOP). Paladins mission is to provide employee ownership and retirement benefits to to the employees of the sellers company while providing private business owners a meaningful exit strategy that preserves their business legacy.